Cost-effectiveness analysis of rheumatic heart disease prevention strategies

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 6, 2013, Pages 715-724

  Manji, Rizwan A ^a   Witt, Julia ^a   Tappia, Paramjit S ^b   Jung, Young ^a   Menkis, Alan H ^a   Ramjiawan, Bram ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

cost effectiveness; developing and low socioeconomic status populations in developed nations; prevention strategies; primary prophylaxis; rheumatic fever; rheumatic heart disease; secondary prophylaxis

Indexed keywords

BENZATHINE PENICILLIN; PENICILLIN DERIVATIVE;

COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSAGE FORM COMPARISON; ECHOCARDIOGRAPH; GROUP A STREPTOCOCCAL INFECTION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MARKOV MODEL; PATIENT COMPLIANCE; PREVALENCE; PRIMARY PREVENTION; PROTOCOL COMPLIANCE; REVIEW; RHEUMATIC HEART DISEASE; SECONDARY PREVENTION; STATISTICAL MODEL; THROAT CULTURE;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; ECHOCARDIOGRAPHY; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MASS SCREENING; PREVALENCE; RHEUMATIC HEART DISEASE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 84887870612     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2013.852470     Document Type: Review

References (41)

1. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 366(9480), 155-168 (2005).
2. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet 379(9819), 953-964 (2012).
3. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special writing group of the committee on rheumatic fever, endocarditis, and Kawasaki Disease of the council on cardiovascular disease in the young of the American Heart Association. J. Am. Med. Assoc. 268(15), 2069-2073 (1992).
4. Karthikeyan G, Zuhlke L, Engel M et al. Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study. Am. Heart J. 163(4), 535-540 (2012).
5. Sliwa K, Zilla P. Rheumatic heart disease: The tip of the iceberg. Circulation 125(25), 3060-3062 (2012).
6. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5(11), 685-694 (2005).
7. Michaud C, Trejo-Gutierrez, Cruz C, Pearson TA. The world Bank Health Sector Priorities Review: Rheumatic Heart Disease. World Bank, Washington, DC, USA, 1-31 (1991).
8. Jaiyesimi F. Chronic rheumatic heart disease in childhood: its cost and economic implications. Trop. Cardiol. 8, 55-59 (1982).
9. Strasser T. Cost-effective control of rheumatic fever in the community. Health Policy 5(2), 159-164 (1985).
10. Tani LY, Veasy LG, Minich LL, Shaddy RE. Rheumatic fever in children younger than 5 years: is the presentation different. Pediatrics 112(5), 1065-1068 (2003).
11. Pelajo CF, Lopez-Benitez JM, Torres JM, de Oliveira SK. Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever. Pediatr. Rheumatol. Online J. 8, 22 (2010).
12. Reeves BM, Kado J, Brook M. High prevalence of rheumatic heart disease in Fiji detected by echocardiography screening. J. Paediatr. Child Health 47(7), 473-478 (2011).
13. Longo-Mbenza B, Bayekula M, Ngiyulu R et al. Survey of rheumatic heart disease in school children of Kinshasa town. Int. J. Cardiol. 63(3), 287-294 (1998).
14. Oli K, Porteous J. Rheumatic heart disease among school children in Addis Ababa City: Awareness and adequacy of its prophylaxis. Ethiop. Med. J. 37(3), 155-161 (1999).
15. Oli K, Asmera J. Rheumatic heart disease in Ethiopia: could it be more malignant. Ethiop. Med. J. 42(1), 1-8 (2005).
16. Marijon E, Ou P, Celermajer DS et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N. Engl. J. Med. 357(5), 470-476 (2007).
17. Saxena A, Ramakrishnan S, Roy A et al. Prevalence and outcome of sunclinical rheumatic heart disease in India: The RHEUMATIC (Rheumatic Heart Echo Utilisation and Monitoring Actuarial Trends in Indian Children) study. Heart 97(24), 2018-2022 (2011).
18. Beaton A, Okello E, Lwabi P et al. Echocardiography in screening for rheumatic heart disease in Ugandan schoolchildren. Circulation 125(25), 3127-3132 (2012).
19. King A. Public health: value of echocardiographic screening for RHD in Ugandan children. Nat. Rev. Cardiol. 9(8), 433 (2012).
20. Marijon E, Celermajer DS, Tafflet M et al. Rheumatic heart disease screening by echocardiography: The inadequacy of World Health Organization criteria for optimizing the diagnosis of subclinical disease. Circulation 120(8), 663-668 (2009).
21. Mirabel M, Celermajer DS, Ferreira B et al. Screening for rheumatic heart disease: evaluation of a simplified echocardiography-based approach. Eur. Heart J. Cardiovasc. Imaging 13(12), 1024-1029 (2012).
22. Kane A, Mirabel M, Touré K et al. Echocardiographic screening for rheumatic heart disease: Age matters. Int. J. Cardiol. doi:10.1016/j.ijcard. 2012.10.090 (2013) (Epub ahead of print).
23. Bhaya M, Beniwal R, Panwar S, Panwar RB. Two years of follow-up validates the echocardiographic criteria for the diagnosis and screening of rheumatic heart disease in asymptomatic populations. Echocardiography 28(9), 929-933 (2011).
24. Steer AC, Carapetis Jr. Acute rheumatic fever and rheumatic heart disease in indigenous populations. Pediatr. Clin. North Am. 56(6), 1401-1419 (2009).
25. Eisenberg MJ. Rheumatic heart disease in the developing world: prevalence, prevention, and control. Eur. Heart J. 14(1), 122-128 (1993).
26. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: A statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics 96(4 Pt 1), 758-764 (1995).
27. Adanja B, Vlajinac H, Jarebinski M. Socioeconomic factors in the etiology of rheumatic fever. J. Hyg. Epidemiol. Microbiol. Immunol. 32(3), 329-335 (1988).
28. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst. Rev. (3), CD002227 (2002).
29. Visvanathan K, Manjarez RC, Zabriskie JB. Rheumatic fever. Curr. Treat. Options Cardiovasc. Med. 1(3), 253-258 (1999).
30. Rayamajhi A, Sharma D, Shakya U. First-episode versus recurrent acute rheumatic fever: is it different. Pediatr. Int. 51(2), 269-275 (2009).
31. Ehrlich JE, Demopoulos BP, Daniel KR Jr, Ricarte MC, Glied S. Cost-effectiveness of treatment options for prevention of rheumatic heart disease from Group A streptococcal pharyngitis in a pediatric population. Prev. Med. 35(3), 250-257 (2002).
32. Coulehan JL, Baacke G, Welty TK, Goldtooth NL. Cost-benefit of a streptococcal surveillance program among Navajo Indians. Public Health Rep. 97(1), 73-77 (1982).
33. Brant LJ, Bender TR, Bross DS. Evaluation of an Alaskan streptococcal control program: importance of the program's intensity and duration. Prev. Med. 15(6), 632-642 (1986).
34. Terreri MT, Ferraz MB, Goldenberg J, Len C, Hilário MO. Resource utilization and cost of rheumatic fever. J. Rheumatol. 28(6), 1394-1397 (2001).
35. Milne RJ, Lennon D, Stewart JM, Vander-Hoorn S, Schuffham PA. Mortality and hospitalization costs of rheumatic fever and rheumatic heart disease in New Zealand. J. Paediatr. Child Health 48(8), 692-697 (2012).
36. Hassell TA, Stuart KL. Rheumatic fever prophylaxis: A three-year study. Br. Med. J. 2(5909), 39-40 (1974).
37. Soudarssanane MB, Karthigeyan M, Mahalakshmy T et al. Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective option. Indian J. Pediatr. 74(6), 567-570 (2007).
38. Irlam J, Mayosi BM, Engel M, Gaziano TA. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: A cost-effectiveness analysis. Circ. Cardiovasc. Qual. Outcomes 6(3). 343-351 (2013).
39. Sonnenberg FA, Beck R. Markov models in medical decision making: A practical guide. Med. Decis. Making 13(4), 322-338 (1993).
40. Sun X, Faunce T. Decision-analytical modelling in health-care economic evaluations. Eur. J. Health Econ. 9(4), 313-323 (2008).
41. Tani LY, Veasy LG, Minich LL, Shaddy RE. Rheumatic fever in children under 5 years. Pediatrics 114(3), 906 (2004).